EP Patent

EP2682387B1 — C7-fluoro substituted tetracycline compounds

Assigned to Tetraphase Pharmaceuticals Inc · Expires 2015-10-07 · 11y expired

What this patent protects

Patent listed against Xerava.

Drugs covered by this patent

Xerava (ERAVACYCLINE DIHYDROCHLORIDE) · Tetraphase Pharms

Patent Metadata

Patent number: EP2682387B1
Jurisdiction: EP
Classification: —
Expires: 2015-10-07
Drug substance claim: No
Drug product claim: No
Assignee: Tetraphase Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.